Quantcast
Last updated on April 18, 2014 at 12:28 EDT

Latest Sirolimus Stories

2012-03-29 23:31:50

FINDINGS: The drug rapamycin has been shown to extend lifespan in lab animals, yet rapamycin has also been linked to impaired glucose tolerance and insulin sensitivity, two hallmarks of diabetes. By teasing apart rapamycin's activity at the cellular level, researchers at Whitehead Institute and the University of Pennsylvania have determined that inhibiting only the protein cluster known as the mechanistic target of rapamycin complex 1 (mTORC1) prolongs life in mice without adversely affecting...

2012-03-29 23:30:40

Rapamycin-induced longevity in mice can be uncoupled from diabetes-inducing side effects A Penn- and MIT-led team explained how rapamycin, a drug that extends mouse lifespan, also causes insulin resistance. The researchers showed in an animal model that they could, in principle, separate the effects, which depend on inhibiting two protein complexes, mTORC1 and mTORC2, respectively. The study suggests that molecules that specifically inhibit mTORC1 may combat age-related diseases without...

2012-03-27 10:23:53

CHICAGO, March 27, 2012 /PRNewswire/ -- OrbusNeich today announced that three-year clinical results presented at the American College of Cardiology's (ACC's) 61st Annual Scientific Session & Expo, ACC.12, demonstrate the safety and feasibility of the Genous Stent for patients with ST-segment elevation myocardial infarction (STEMI) and showed no incidence of very late stent thrombosis (ST). Additional analyses from the REMEDEE trial for OrbusNeich's Combo Dual Therapy Stent...

2012-03-22 06:24:16

HONG KONG, March 22, 2012 /PRNewswire/ -- OrbusNeich today announced the publication of a review article about the company's Genous technology in the February edition of Minerva Cardioangiologica. The article presents ex vivo and preclinical data showing that the endothelial progenitor cell (EPC) capture technology employed by both the company's Genous Stent and Combo Dual Therapy Stent effectively promotes endothelialization and reduces thrombogenicity to address the...

2012-02-29 09:26:37

(Ivanhoe Newswire) — Researchers have discovered how a protein "master regulator" goes awry, leading to metastasis, the fatal step of cancer. The protein mTOR is a "master regulator" of human protein synthesis. It helps normal cells sense nutrients and control cell growth and metabolism. But in many forms of cancer, this process goes awry, and mTOR reprograms normal cells to aberrantly divide, invade and metastasize. In the human body, mTOR is a molecular sensor that helps cells...

2012-01-27 12:00:00

Drug helps keep cancer from progressing SILVER SPRING, Md., Jan. 27, 2012 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes in the kidney. Inlyta...

2012-01-05 08:00:00

HONG KONG, Jan. 5, 2012 /PRNewswire/ -- OrbusNeich today announced that 12-month follow-up data from a post-hoc analysis of the e-HEALING registry demonstrate that the company's Genous Stent achieves good, comparable clinical and safety outcomes in patients discontinuing dual antiplatelet therapy (DAPT) at 30 days and at six months. According to the study, clinical outcomes in patients treated with Genous were not associated with the duration of DAPT. The study has been...

2011-12-08 16:32:18

In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progression-free survival, according to research from The University of Texas MD Anderson Cancer Center. The study, known as Breast Cancer Trials of Oral Everolimus (BOLERO-2),...

2011-12-07 17:34:00

EAST HANOVER, N.J., Dec. 7, 2011 /PRNewswire/ -- Updated results of a Phase III study of Afinitor® (everolimus) tablets plus exemestane, a hormonal therapy, show everolimus provided additional time women with advanced breast cancer lived without their disease progressing (progression-free survival)(1). The study findings, which represent an additional five months of follow-up, were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium...

2011-12-05 10:19:00

Imaging of patients with a rare condition associated with autism reveals altered nerve-fiber pathways <font size="2" face="Arial">BOSTON </font>, Dec. 5, 2011 /PRNewswire-USNewswire/ -- It's still unclear what's different in the brains of people with autism spectrum disorders (ASDs), but evidence from genetic and cell studies points to abnormalities in how brain cells (neurons) connect to each other. A study at Children's Hospital Boston now provides visual evidence...